Managing Transition in Patients Treated with Growth Hormone

Growth hormone (GH) promotes growth in children, but is also essential for bone strength, body composition, metabolic factors, such as lipid profile, and maintenance of quality of life. The Merck KGaA (Germany) funded “360° GH in Europe” meeting, held in Lisbon, Portugal, in June 2016, comprised thr...

Full description

Bibliographic Details
Main Authors: Berthold P. Hauffa, Philippe Touraine, Tanya Urquhart-Kelly, Ekaterina Koledova
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-12-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fendo.2017.00346/full
id doaj-4c3dcf020dc2420992eeb42234324901
record_format Article
spelling doaj-4c3dcf020dc2420992eeb422343249012020-11-24T20:44:21ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922017-12-01810.3389/fendo.2017.00346296728Managing Transition in Patients Treated with Growth HormoneBerthold P. Hauffa0Philippe Touraine1Tanya Urquhart-Kelly2Ekaterina Koledova3Department of Pediatric Endocrinology, University of Duisburg-Essen, Essen, GermanyDepartment of Endocrinology and Reproductive Medicine, Centre des Maladies Endocriniennes Rares de la Croissance et du Développement, Paris, FranceDepartment of Nursing and Midwifery, Sheffield Hallam University, Sheffield, United KingdomGlobal Medical Affairs, Merck KGaA, Darmstadt, GermanyGrowth hormone (GH) promotes growth in children, but is also essential for bone strength, body composition, metabolic factors, such as lipid profile, and maintenance of quality of life. The Merck KGaA (Germany) funded “360° GH in Europe” meeting, held in Lisbon, Portugal, in June 2016, comprised three sessions entitled “Short Stature Diagnosis and Referral,” “Optimizing Patient Management and Adherence,” and “Managing Transition.” The scientific program covered all stages of pediatric GH treatment, and reported here are the outcomes of the third session of the meeting, which considered transition from pediatric GH treatment to teenage and young adult GH therapy. A large number of patients with chronic diseases, including GH deficiency, drop out of therapy during the transition period. Multiple factors are associated with this, such as lack of understanding of the disease process, insufficient knowledge of treatment options, the patient becoming more independent, and requirement for interaction with a new set of health-care workers. Education regarding disease management and treatment options should be provided from an early age and right through the transition period. However, endocrine specialists will view the transition period differently, depending on whether they are pediatric endocrinologists who mainly deal with congenital diseases, in which auxology is important, or adult endocrinologists who are more concerned with body composition and metabolic factors. View points of both a pediatric and an adult endocrine specialist are presented, together with a case study outlining practical aspects of transition. It was noted in the meeting discussion that having one person to guide a patient through transition from an early age is important, but may be constrained by various factors such as finances, and options will differ by country.http://journal.frontiersin.org/article/10.3389/fendo.2017.00346/fullgrowth hormone deficiencypediatricadolescenttransitionpersonalized medicineendocrinology
collection DOAJ
language English
format Article
sources DOAJ
author Berthold P. Hauffa
Philippe Touraine
Tanya Urquhart-Kelly
Ekaterina Koledova
spellingShingle Berthold P. Hauffa
Philippe Touraine
Tanya Urquhart-Kelly
Ekaterina Koledova
Managing Transition in Patients Treated with Growth Hormone
Frontiers in Endocrinology
growth hormone deficiency
pediatric
adolescent
transition
personalized medicine
endocrinology
author_facet Berthold P. Hauffa
Philippe Touraine
Tanya Urquhart-Kelly
Ekaterina Koledova
author_sort Berthold P. Hauffa
title Managing Transition in Patients Treated with Growth Hormone
title_short Managing Transition in Patients Treated with Growth Hormone
title_full Managing Transition in Patients Treated with Growth Hormone
title_fullStr Managing Transition in Patients Treated with Growth Hormone
title_full_unstemmed Managing Transition in Patients Treated with Growth Hormone
title_sort managing transition in patients treated with growth hormone
publisher Frontiers Media S.A.
series Frontiers in Endocrinology
issn 1664-2392
publishDate 2017-12-01
description Growth hormone (GH) promotes growth in children, but is also essential for bone strength, body composition, metabolic factors, such as lipid profile, and maintenance of quality of life. The Merck KGaA (Germany) funded “360° GH in Europe” meeting, held in Lisbon, Portugal, in June 2016, comprised three sessions entitled “Short Stature Diagnosis and Referral,” “Optimizing Patient Management and Adherence,” and “Managing Transition.” The scientific program covered all stages of pediatric GH treatment, and reported here are the outcomes of the third session of the meeting, which considered transition from pediatric GH treatment to teenage and young adult GH therapy. A large number of patients with chronic diseases, including GH deficiency, drop out of therapy during the transition period. Multiple factors are associated with this, such as lack of understanding of the disease process, insufficient knowledge of treatment options, the patient becoming more independent, and requirement for interaction with a new set of health-care workers. Education regarding disease management and treatment options should be provided from an early age and right through the transition period. However, endocrine specialists will view the transition period differently, depending on whether they are pediatric endocrinologists who mainly deal with congenital diseases, in which auxology is important, or adult endocrinologists who are more concerned with body composition and metabolic factors. View points of both a pediatric and an adult endocrine specialist are presented, together with a case study outlining practical aspects of transition. It was noted in the meeting discussion that having one person to guide a patient through transition from an early age is important, but may be constrained by various factors such as finances, and options will differ by country.
topic growth hormone deficiency
pediatric
adolescent
transition
personalized medicine
endocrinology
url http://journal.frontiersin.org/article/10.3389/fendo.2017.00346/full
work_keys_str_mv AT bertholdphauffa managingtransitioninpatientstreatedwithgrowthhormone
AT philippetouraine managingtransitioninpatientstreatedwithgrowthhormone
AT tanyaurquhartkelly managingtransitioninpatientstreatedwithgrowthhormone
AT ekaterinakoledova managingtransitioninpatientstreatedwithgrowthhormone
_version_ 1716817582725529600